ANNX Stock Price, Annexon, Inc. Quote, Chart

Market Summary

USD5.11-0.63

Delayed

-10.98%

ANNX Alerts

1 major insider buys recently.

ANNX Stock Price

View Fullscreen

ANNX RSI Chart

ANNX Valuation

Market Cap

385.0M

Price/Earnings (Trailing)

-2.87

EV/EBITDA

-2.65

Price/Free Cashflow

-3.17

MarketCap/EBT

-4.73

ANNX Price/Sales (Trailing)

ANNX Profitability

Return on Equity

-53.58%

Return on Assets

-45.1%

Free Cashflow Yield

-31.52%

ANNX Fundamentals

ANNX Earnings

Earnings (TTM)

-134.2M

Earnings Growth (Yr)

18.88%

Earnings Growth (Qtr)

14.13%

Breaking Down ANNX Revenue

Last 7 days

-18.0%

Last 30 days

-23.6%

Last 90 days

11.1%

Trailing 12 Months

7.1%

How does ANNX drawdown profile look like?

ANNX Financial Health

Current Ratio

14.72

ANNX Investor Care

Shares Dilution (1Y)

64.22%

Diluted EPS (TTM)

-1.77

Tracking the Latest Insider Buys and Sells of Annexon, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 08, 2024	carson william h.	bought	19,411	6.066	3,200	-
Feb 20, 2024	overdorf michael	sold	-10,691	5.48	-1,951	evp & chief business officer
Feb 20, 2024	yednock ted	sold	-14,348	5.51	-2,604	evp & chief innovation officer
Feb 20, 2024	lew jennifer	sold	-14,339	5.53	-2,593	evp & chief financial officer
Feb 16, 2024	overdorf michael	acquired	-	-	39,000	evp & chief business officer
Feb 16, 2024	artis dean richard	acquired	-	-	39,000	evp & chief scientific officer
Feb 16, 2024	yednock ted	acquired	-	-	39,000	evp & chief innovation officer
Feb 16, 2024	dananberg jamie	acquired	-	-	39,000	chief medical officer
Feb 16, 2024	lew jennifer	acquired	-	-	39,000	evp & chief financial officer
Feb 12, 2024	lew jennifer	sold	-10,021	5.54	-1,809	evp & chief financial officer

Which funds bought or sold ANNX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 15, 2024	Sunbelt Securities, Inc.	new	-	5,736	5,736	-%
Apr 12, 2024	DNB Asset Management AS	new	-	257,482	257,482	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 27, 2024	NOMURA HOLDINGS INC	sold off	-100	-39,294	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	reduced	-87.15	-2,226	731	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.73	4,192,990	8,663,800	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	131	2,007,440	2,587,190	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.4	49,243	102,999	-%
Feb 26, 2024	Virtu Financial LLC	new	-	221,000	221,000	0.02%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	new	-	57,000	57,000	-%

Are Funds Buying or Selling ANNX?

Are funds buying ANNX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ANNX

No. of Funds

ANNX Alerts

1 major insider buys recently.

Unveiling Annexon, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	venrock healthcare capital partners ii, l.p.	0.0%	0	SC 13G/A
Feb 14, 2024	fairmount funds management llc	0.4%	322,893	SC 13G/A
Feb 14, 2024	biotechnology value fund l p	4.7%	3,673,570	SC 13G/A
Feb 14, 2024	eventide asset management, llc	0.0%	0	SC 13G/A
Feb 14, 2024	redmile group, llc	9.9%	8,083,776	SC 13G/A
Feb 14, 2024	citadel advisors llc	1.3%	6	SC 13G/A
Feb 13, 2024	bain capital life sciences fund, l.p.	9.99%	8,061,719	SC 13G/A
Feb 13, 2024	logos global management lp	8.3%	6,944,444	SC 13G/A
Feb 12, 2024	point72 asset management, l.p.	6.2%	4,856,400	SC 13G
Feb 07, 2024	adage capital partners gp, l.l.c.	7.15%	5,645,761	SC 13G/A

Recent SEC filings of Annexon, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 10, 2024	4	Insider Trading
Apr 05, 2024	424B5	Prospectus Filed
Apr 01, 2024	EFFECT	EFFECT
Mar 26, 2024	10-K	Annual Report
Mar 26, 2024	8-K	Current Report
Mar 26, 2024	S-3	S-3
Mar 26, 2024	S-8	Employee Benefits Plan
Mar 04, 2024	8-K	Current Report
Feb 21, 2024	4	Insider Trading
Feb 21, 2024	4	Insider Trading

Peers (Alternatives to Annexon, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.7B	6.8B	-0.04%	-27.89%	-8.41	5.79	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.5B	1.8B	-1.63%	-28.69%	-42.01	10.12	76.23%	61.08%
BMRN	17.2B	2.4B	8.39%	-9.36%	102.31	7.09	15.42%	18.43%
INCY	11.9B	3.7B	-8.82%	-29.04%	20	3.23	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-8.69%	-36.86%	-11.82	15.75	425.83%	18.94%
BBIO	4.4B	-	-8.20%	68.33%	-6.81	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-8.92%	-2.36%	-13.62	12.04	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.30%	-24.47%	-9.88	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-11.77%	-45.95	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-3.36%	-14.10%	25.63	4.6	85.90%	-14.05%
NVAX	557.0M	983.7M	-24.76%	-57.93%	-1.02	0.57	-50.36%	17.16%
CRBP	432.8M	881.7K	-5.56%	294.36%	-9.7	466.16	-77.61%	-5.33%
INO	225.3M	4.9M	-10.24%	-14.54%	-1.67	46.29	-54.97%	51.72%
IBIO	6.8M	2.1M	86.67%	92.16%	-0.25	2.14	-13.45%	66.37%

Annexon, Inc. News

Latest updates

Annexon, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	46.1%	298	204	233	269	285	313	221	251	287	310	332	333	356	376	131	50.00
Current Assets	56.0%	264	169	198	233	248	275	181	211	248	275	304	331	354	374	126	45.00
Cash Equivalents	69.1%	225	133	114	144	140	212	106	114	76.00	70.00	101	208	269	371	125	44.00
Net PPE	-3.5%	15.00	15.00	16.00	16.00	17.00	17.00	17.00	18.00	18.00	12.00	5.00	1.00	2.00	2.00	2.00	2.00
Liabilities	0.3%	47.00	47.00	48.00	54.00	54.00	52.00	53.00	50.00	55.00	46.00	36.00	12.00	12.00	10.00	14.00	6.00
Current Liabilities	4.4%	18.00	17.00	18.00	23.00	22.00	20.00	20.00	17.00	22.00	12.00	10.00	11.00	11.00	9.00	13.00	5.00
Shareholder's Equity	59.8%	251	157	185	215	231	261	168	201	232	264	295	321	344	365	-	-
Retained Earnings	-5.1%	-572	-544	-512	-476	-438	-403	-368	-331	-296	-258	-223	-192	-165	-142	-127	-102
Additional Paid-In Capital	17.3%	823	702	697	692	670	665	537	533	528	523	519	514	510	508	9.00	2.00
Accumulated Depreciation	-	5.00	-	-	-	3.00	-	-	-	-	-	3.00	3.00	2.00	2.00	2.00	1.00
Shares Outstanding	4.8%	78.00	75.00	75.00	74.00	48.00	69.00	39.00	39.00	39.00	38.00	38.00	38.00	38.00	28.00	-	-
Float	-	-	-	121	-	-	-	125	-	-	-	750	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Cashflow From Operations	17.0%	-23,477	-28,291	-36,381	-32,993	-27,139	-30,718	-28,164	-30,288	-28,321	-29,715	-24,634	-23,440	-19,256	-13,584	-10,246	-10,001	-	-	-
Share Based Compensation	-4.0%	4,367	4,549	4,660	4,607	4,833	4,911	4,520	4,252	4,355	4,428	4,517	2,962	1,991	1,471	763	663	-	-	-
Cashflow From Investing	-104.6%	-2,183	47,838	5,531	19,517	-43,615	14,098	19,709	68,251	33,697	-1,278	-83,074	-37,581	-82,872	-276	-	-	-	-	-
Cashflow From Financing	-	117,598	-	345	17,581	108	122,668	113	19.00	948	-73.00	652	268	-	259,781	101,666	-571	-	-	-

ANNX Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 113,756	$ 112,501
General and administrative	29,967	33,098
Total operating expenses	143,723	145,599
Loss from operations	(143,723)	(145,599)
Interest and other income, net	9,486	3,652
Net loss	$ (134,237)	$ (141,947)
Net loss per share, basic	$ (1.77)	$ (2.6)
Net loss per share, diluted	$ (1.77)	$ (2.6)
Weighted-average shares used in computing net loss per share, basic	75,673,081	54,673,572
Weighted-average shares used in computing net loss per share, diluted	75,673,081	54,673,572

ANNX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 225,110	$ 140,020
Short-term investments	34,606	102,637
Prepaid expenses and other current assets	4,144	5,441
Total current assets	263,860	248,098
Restricted cash	1,032	1,032
Property and equipment, net	14,773	16,838
Operating lease right-of-use assets	18,009	19,128
Total assets	297,674	285,096
Current liabilities:
Accounts payable	5,487	7,416
Accrued liabilities	10,235	13,448
Operating lease liabilities, current	2,165	1,316
Other current liabilities	41	180
Total current liabilities	17,928	22,360
Operating lease liabilities, non-current	29,190	31,542
Total liabilities	47,118	53,902
Commitments and contingencies (Note 5)
Stockholders’ equity:
Common stock, $0.001 par value; 300,000,000 shares authorized as of December 31, 2023 and 2022, respectively; 78,369,099 and 47,722,995 shares issued and outstanding as of December 31, 2023 and 2022, respectively	78	48
Additional paid-in capital	823,029	669,780
Accumulated other comprehensive loss	(52)	(372)
Accumulated deficit	(572,499)	(438,262)
Total stockholders' equity	250,556	231,194
Total liabilities and stockholders’ equity	$ 297,674	$ 285,096

About Annexon, Inc.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barrÃƒÂ© syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

CEO	Mr. Douglas Love Esq., J.D.
WEBSITE	annexonbio.com
INDUSTRY	Biotechnology
EMPLOYEES	77

Annexon, Inc. Frequently Asked Questions

What is the ticker symbol for Annexon, Inc.? What does ANNX stand for in stocks?

ANNX is the stock ticker symbol of Annexon, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Annexon, Inc. (ANNX)?

As of Tue Apr 16 2024, market cap of Annexon, Inc. is 385 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ANNX stock?

You can check ANNX's fair value in chart for subscribers.

What is the fair value of ANNX stock?

You can check ANNX's fair value in chart for subscribers. The fair value of Annexon, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Annexon, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ANNX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Annexon, Inc. a good stock to buy?

The fair value guage provides a quick view whether ANNX is over valued or under valued. Whether Annexon, Inc. is cheap or expensive depends on the assumptions which impact Annexon, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANNX.